Check out your Company Bowl for anonymous work chats.
New Clinical Evidence Links Ceribell Point-of-Care EEG to Shorter Hospital Stays and Better Functional Outcomes Compared to Conventional EEG
CeriBell, Inc. Announces Closing of Upsized Initial Public Offering and Full Exercise of the Underwriters' Option to Purchase Additional Shares
Ceribell Announces Pricing of Upsized IPO IPO funding positions Ceribell to transform the diagnosis and management of patients with serious neurological conditions
Ceribell announced on July 22, 2024, the Publication of a Study Demonstrating a Significant Reduction in Length of ICU Stays and Better Patient Outcomes with Ceribell Point-of-Care EEG Compared to Conventional EEG.
Ceribell announced on August 2, 2023, that its new software ClarityPro has received 510(k) clearance from the U.S. Food and Drug Administration (FDA) for the indication of diagnosing Electrographic Status Epilepticus (ESE).
Ceribell announced on March 2, 2023, that it has been named to Fast Company’s 2023 List of the World’s Most Innovative Companies.
Ceribell announced on Sept 08, 2022, that it has received Breakthrough Device Designation for its delirium indication from the United States Food and Drug Administration (FDA).
Ceribell announced on Sept 21, 2022, that it has closed a $50 million financing round led by new investor Ally Bridge Group, with participation from existing shareholders.
